View in EDS

Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting.

Saved in:
Bibliographic Details
Title: Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting.
Authors: Wenzel, Mike, Hoeh, Benedikt, Wagner, Nele, Koll, Florestan, Siech, Carolin, Humke, Clara, Steuber, Thomas, Graefen, Markus, Tilki, Derya, Kluth, Luis, Traumann, Miriam, Banek, Séverine, Chun, Felix K. H., Mandel, Philipp
Source: Journal of the American Geriatrics Society. Sep2024, Vol. 72 Issue 9, p2700-2708. 9p.
Subjects: Antineoplastic agents, Docetaxel, Academic medical centers, T-test (Statistics), Kruskal-Wallis Test, Life expectancy, Prostate tumors, Treatment effectiveness, Retrospective studies, Descriptive statistics, Chi-squared test, Multivariate analysis, Metastasis, Kaplan-Meier estimator, Cancer chemotherapy, Androgen receptors, Overall survival, Proportional hazards models, Regression analysis, Old age
Geographic Terms: Germany
Abstract: Background: The landscape of systemic therapies for metastatic hormone‐sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults. Methods: We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70–74 versus ≥75–79 versus ≥80 years at metastatic occurrence. Subsequently, uni‐ and multivariable time to mCRPC and overall survival analyses were performed. Results: Of 494 older adults, 217 (44%) were 70–74 versus 180 (36%) 75–79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p < 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30–39% of patients and docetaxel with 9% in age group 70–74 years and 6% and 3% in age groups 75–79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p < 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70–74 (16%), relative to 4% and 3% in 75‐79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3). Conclusions: Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy. [ABSTRACT FROM AUTHOR]
Copyright of Journal of the American Geriatrics Society is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 179392296
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Wenzel%2C+Mike%22&quot;&gt;Wenzel, Mike&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hoeh%2C+Benedikt%22&quot;&gt;Hoeh, Benedikt&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Wagner%2C+Nele%22&quot;&gt;Wagner, Nele&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Koll%2C+Florestan%22&quot;&gt;Koll, Florestan&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Siech%2C+Carolin%22&quot;&gt;Siech, Carolin&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Humke%2C+Clara%22&quot;&gt;Humke, Clara&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Steuber%2C+Thomas%22&quot;&gt;Steuber, Thomas&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Graefen%2C+Markus%22&quot;&gt;Graefen, Markus&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tilki%2C+Derya%22&quot;&gt;Tilki, Derya&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kluth%2C+Luis%22&quot;&gt;Kluth, Luis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Traumann%2C+Miriam%22&quot;&gt;Traumann, Miriam&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Banek%2C+S&#233;verine%22&quot;&gt;Banek, S&#233;verine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chun%2C+Felix+K%2E+H%2E%22&quot;&gt;Chun, Felix K. H.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mandel%2C+Philipp%22&quot;&gt;Mandel, Philipp&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Journal+of+the+American+Geriatrics+Society%22&quot;&gt;Journal of the American Geriatrics Society&lt;/searchLink&gt;. Sep2024, Vol. 72 Issue 9, p2700-2708. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antineoplastic+agents%22&quot;&gt;Antineoplastic agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Docetaxel%22&quot;&gt;Docetaxel&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Academic+medical+centers%22&quot;&gt;Academic medical centers&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22T-test+%28Statistics%29%22&quot;&gt;T-test (Statistics)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Kruskal-Wallis+Test%22&quot;&gt;Kruskal-Wallis Test&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Life+expectancy%22&quot;&gt;Life expectancy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Prostate+tumors%22&quot;&gt;Prostate tumors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Treatment+effectiveness%22&quot;&gt;Treatment effectiveness&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Retrospective+studies%22&quot;&gt;Retrospective studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Descriptive+statistics%22&quot;&gt;Descriptive statistics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Chi-squared+test%22&quot;&gt;Chi-squared test&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Multivariate+analysis%22&quot;&gt;Multivariate analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Metastasis%22&quot;&gt;Metastasis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Kaplan-Meier+estimator%22&quot;&gt;Kaplan-Meier estimator&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cancer+chemotherapy%22&quot;&gt;Cancer chemotherapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Androgen+receptors%22&quot;&gt;Androgen receptors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Overall+survival%22&quot;&gt;Overall survival&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Proportional+hazards+models%22&quot;&gt;Proportional hazards models&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Regression+analysis%22&quot;&gt;Regression analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Old+age%22&quot;&gt;Old age&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Germany%22&quot;&gt;Germany&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: The landscape of systemic therapies for metastatic hormone‐sensitive (mHSPC) and castration resistant prostate cancer (mCRPC) extensively improved within the last decades resulting in a significantly prolonged overall survival. However, subgroup analyses of phase III trials suggest potentially different overall survival outcomes for older adults. Methods: We relied on our institutional metastatic prostate cancer database to identify mHSPC and subsequently mCRPC patients. Older adults were stratified according to age groups 70–74 versus ≥75–79 versus ≥80 years at metastatic occurrence. Subsequently, uni‐ and multivariable time to mCRPC and overall survival analyses were performed. Results: Of 494 older adults, 217 (44%) were 70–74 versus 180 (36%) 75–79 versus 97 (20%) ≥80 years old. Rates of local prostate cancer treatment differed significantly between all three groups (p &lt; 0.01). Regarding mHSPC treatment, androgen receptor signaling inhibitors (ARSI) were administered in 30–39% of patients and docetaxel with 9% in age group 70–74 years and 6% and 3% in age groups 75–79 years and ≥80 years. Regarding mCRPC treatment, significant differences between treatment proportions were observed (p &lt; 0.01). Most common treatment was ARSI for all three groups. Conversely, chemotherapy was more frequently administered in patients aged 70–74 (16%), relative to 4% and 3% in 75‐79 year and ≥80 year aged patients. In univariable and multivariable time to mCRPC analyses, overall survival in mHSPC and OS in mCRPC analyses, no significant differences between all three age groups were observed (all p ≥ 0.3). Conclusions: Treatment patterns differ significantly between older adults with metastatic prostate cancer. However, these differences may not result in differences of overall life expectancy. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Journal of the American Geriatrics Society is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=179392296
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/jgs.19045
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 2700
    Subjects:
      – SubjectFull: Antineoplastic agents
        Type: general
      – SubjectFull: Docetaxel
        Type: general
      – SubjectFull: Academic medical centers
        Type: general
      – SubjectFull: T-test (Statistics)
        Type: general
      – SubjectFull: Kruskal-Wallis Test
        Type: general
      – SubjectFull: Life expectancy
        Type: general
      – SubjectFull: Prostate tumors
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Retrospective studies
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Chi-squared test
        Type: general
      – SubjectFull: Multivariate analysis
        Type: general
      – SubjectFull: Metastasis
        Type: general
      – SubjectFull: Kaplan-Meier estimator
        Type: general
      – SubjectFull: Cancer chemotherapy
        Type: general
      – SubjectFull: Androgen receptors
        Type: general
      – SubjectFull: Overall survival
        Type: general
      – SubjectFull: Proportional hazards models
        Type: general
      – SubjectFull: Regression analysis
        Type: general
      – SubjectFull: Old age
        Type: general
      – SubjectFull: Germany
        Type: general
    Titles:
      – TitleFull: Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real‐world setting.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wenzel, Mike
      – PersonEntity:
          Name:
            NameFull: Hoeh, Benedikt
      – PersonEntity:
          Name:
            NameFull: Wagner, Nele
      – PersonEntity:
          Name:
            NameFull: Koll, Florestan
      – PersonEntity:
          Name:
            NameFull: Siech, Carolin
      – PersonEntity:
          Name:
            NameFull: Humke, Clara
      – PersonEntity:
          Name:
            NameFull: Steuber, Thomas
      – PersonEntity:
          Name:
            NameFull: Graefen, Markus
      – PersonEntity:
          Name:
            NameFull: Tilki, Derya
      – PersonEntity:
          Name:
            NameFull: Kluth, Luis
      – PersonEntity:
          Name:
            NameFull: Traumann, Miriam
      – PersonEntity:
          Name:
            NameFull: Banek, Séverine
      – PersonEntity:
          Name:
            NameFull: Chun, Felix K. H.
      – PersonEntity:
          Name:
            NameFull: Mandel, Philipp
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 00028614
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Journal of the American Geriatrics Society
              Type: main
ResultId 1